Diabetic nephropathy is one of the major causes of increased morbidity and mortality among diabetic patients worldwide, where it remains the single largest cause of chronic kidney disease.[@b1-asm-1-46] This complication has put a major burden on health care systems, particularly in developing countries.[@b2-asm-1-46] Saudi Arabia is one of the leading countries in terms of diabetes prevalence and associated complications,[@b3-asm-1-46],[@b4-asm-1-46] where almost one-third of type 2 Saudi diabetic population has diabetic nephropathy.[@b5-asm-1-46] In 2011, it was estimated that 42.5% of end stage renal disease (ESRD) cases in Saudi Arabia were related to diabetes,[@b6-asm-1-46] and the cost for dialysis in this country amounts to SR 173 784 (US\$ 46 332) per patient per year.[@b7-asm-1-46]

Diabetic nephropathy needs to be extensively studied to explore risk factors that might be related to its gradually increasing incidence in Saudi Arabia,[@b5-asm-1-46] especially when it is known that diabetic patients in this country have higher rate of complications,[@b3-asm-1-46] which can be attributed to poor diabetes control in addition to genetic factors that may result from the high rate of consanguineous marriage.[@b8-asm-1-46] For that reason the Strategic Center for Diabetes Research initiated the Saudi Diabetes Kidney Disease (SAUDI-DKD) study, selecting a cohort of type 2 diabetic patients. This study will evaluate genetics, proteomics, and biomarkers related to diabetic kidney disease. Such a holistic approach will be useful in early detection and prevention of this devastating and costly complication. This article describes the SAUDI-DKD cohort from a clinical point of view to evaluate hematology, liver and biochemical markers related to type 2 diabetic patients with various degrees of albuminuria and chronic kidney disease (CKD).

PATIENTS AND METHODS
====================

The SAUDI-DKD study was designed to be a hospital- based cohort study of four groups of Saudi type 2 diabetic patients defined according to the American Diabetes Association (ADA) criteria 2005 with or without diabetic nephropathy.[@b9-asm-1-46] Normoalbuminuria, microalbuminuria, and macroalbuminuria patients were recruited from two university hospitals: King Abdulaziz Hospital, King Khalid Hospital and other two Ministry of Health general hospitals: Al-Iman Hospital and King Salman bin Abdulaziz Hospital. Patients with ESRD were recruited either from the dialysis units of those hospitals or from the hemodialysis care project of The Custodian of the Two Holy Mosques King Abdullah bin Abdulaziz Al-Saud Foundation for Humanitarian Affairs. Any diabetic patients who developed ESRD unrelated to diabetes were excluded.

Subject sampled by convenience between 1 April 2014 and 18 June 2015 were type 2 diabetic patients of either gender aged between 35 and 70 years and with a diabetes duration that exceeded 10 years. Pregnant women, patients with history of smoking and patients suffering from cancer or any renal disease were excluded. Patients exposed to radiocontrast agents or drugs that might affect their kidney functions like aminoglycoside, amphotericin, beta-lactam antibiotics, methotrexate, cisplatin, cyclosporine, or tacrolimus were excluded.

All subjects signed the consent form and their clinical data were obtained during the interview. On a mutually agreed day, patients were asked to attend the clinic after overnight fasting for blood and urine sampling. Patients were then classified according to their estimated glomerular filtration rate (eGFR) value into two groups with patients having eGRF \<15 mL/min/1.73 m^2^ who had ESRD and were on hemodialysis and 480 subjects had eGFR of ≥30 mL/min/1.73 m^2^. Subjects in the second group were reclassified according to their urinary albumin excretion into three groups using ADA diabetic nephropathy stages cutoff values for urinary albumin excretion. Personal and social data were collected from all subjects using a pre-designed data collection sheet. Diabetes-related data including duration, family history, and presence of other chronic diabetes complications namely: vasculopathy, retinopathy and neuropathy and associated diseases, such as hypertension and hyperlipidemia, were collected from medical records. Anthropometric measurements and blood pressure were measured during the clinical visit.

Each subject was asked to fast for more than 10 hours and 20 cc of venous blood sample was collected using an EDTA tube for hematology including hemoglobin A1c (HbA1c) and a plain tube for serum to assess all other biochemistry markers. Each subject was asked to provide a fresh 10 cc urine sample in plain tube for ACR assessment. All the samples were transferred using a portable refrigerator with temperature adjusted between 4 and 8 C to the Strategic Center for Diabetes Research Central Laboratory.

The hematological parameters were determined using Mindray BC-3200 autohematology analyzer (Mindray Medical International Limited, Shenzhen, China), while liver function, renal function and lipid profile as well as urine parameters were performed in a RX Daytona clinical chemistry analyzer by Randox (UK). The HbA1c was assessed using a latex agglutination inhibition assay using the same chemistry analyzer. Insulin and c-peptide measurement were conducted using the biochip assay methodology in a Randox Evidence Biochip analyzer by Randox (UK) which is based on the standard immunoassay technique. Blood glucose assessment was done using glucose oxidase-peroxidase methodology, and serum cholesterol assessment was done using cholesterol oxidase-peroxidase methodology. The HDL, LDL and triglyceride were measured using direct and glycerol kinase oxidase-peroxidase methodology. The eGFR and albumin creatinine ratio (ACR) were calculated by specific calculators.[@b10-asm-1-46],[@b11-asm-1-46] This study was reviewed and approved by the institutional review (IRB), at College of Medicine, King Saud University.

Data were analyzed using IBM SPSS statistical package version 21. Continuous variables were expressed as mean and standard deviation (SD), and categorical variables were expressed as percentages. The *t* test was used for continuous variables and the chi square test was used for categorical variables. Homeostatic model assessment (HOMA) insulin resistance (IR) and β-cell function (B) were calculated using the software HOMA 2 calculator.[@b12-asm-1-46] The association between different parameters and stages of diabetic nephropathy was expressed as odds ratio (OR) and its 95% confidence intervals (CI) using a multivariate regression analysis model. A *P* value of less than .05 was used as a level of significance.

RESULTS
=======

Of 6714 Saudi type 2 diabetic patients screened, 1512 were eligible and 741 were recruited after exclusions. One hundred one had to be excluded (unavailability of urine sample for 64 subjects and having a hemolyzed blood sample in 37 subjects) ([Figure 1](#f1-asm-1-46){ref-type="fig"}). Patients with nephropathy were older, had a longer diabetes duration, and had lower monthly income than patients without nephropathy ([Table 1](#t1-asm-1-46){ref-type="table"}). The mean body mass index (BMI) was significantly lower among patients with nephropathy and was lowest among ESRD patients (*P*=.008). Despite control measures, systolic blood pressure (SBP) was significantly higher among patients with nephropathy (*P*\<.001), which was not the case for diastolic blood pressure (DBP). The mean eGFR for nephropathic patients was 47.98 (45.65) mL/min/1.73 m^2^ compared to 79.01 (46.17) mL/min/1.73 m^2^ for patients with microalbuminuria and 50.14 (21.91) mL/min/1.73 m^2^ for patients with macroalbuminuria. The mean eGFR for cases with ESRD was 7.79 (4.32) mL/min/1.73 m^2^ ([Table 1](#t1-asm-1-46){ref-type="table"}).

Subjects with diabetic nephropathy were older than those without nephropathy , but age distribution was normal in both groups ([Figure 2](#f2-asm-1-46){ref-type="fig"}) while ESRD cases had a mean age of more than 60 years. The longer the duration of diabetes, the more frequent diabetic nephropathy increased with longer diabetes duration, being the highest for a diabetes duration between 15 and 30 years. Positive family history of diabetes was more frequent among patients without nephropathy when compared with patients with nephropathy which is the same finding when looking at family history of renal disease. On the other hand, out of patients with positive family history of renal disease, 64.55% were having nephropathy, while 35.45% were among patients without nephropathy ([Table 1](#t1-asm-1-46){ref-type="table"}).

Diabetic nephropathy in the studied cohort was significantly more frequent among lower social class. Subjects with diabetic nephropathy, had significantly higher rate of retinopathy and vasculopathy with *P* \<.001, but not neuropathy when compared with patients without diabetic nephropathy. Both hypertension and hyperlipidemia were significantly more frequent among subjects with diabetic nephropathy (*P*\<.001) as shown in [Table 2](#t2-asm-1-46){ref-type="table"}.

In [Table 3](#t3-asm-1-46){ref-type="table"}, subjects with microalbuminuria demonstrated significantly high mean values of white blood cells (WBC) and mean corpuscular hemoglobin (MCH) when compared to patients with without diabetic nephropathy. The subjects with microalbuminuria had demonstrated decreased mean values for RBCs count, hemoglobin (Hb), hematocrit (Hct), mean corpuscular volume (MCV), Red blood cell distribution width (RDW-SD) and Red blood cell distribution width (RDW-CV), while significantly increased mean values of WBC and mean corpuscular hemoglobin concentration (MCHC) compared with those without nephropathy (*P* value=. 015 and 0.37 respectively). The subjects with ESRD showed a significant decrease in the mean values of Hb, RBC, Hct, platelets and plateletcrit (PCT) but a significant increase in MCV, MCH, MCHC, RDW-SD, and RDW-CV.

The mean values of potassium, urea, creatinine and uric acid were significantly increasing with the progression of diabetic nephropathy. Total protein and albumin were significantly higher for subjects with microalbuminuria, while subjects with microalbuminuria did not show any significant difference in the mean values of both proteins. The LDH and gamma-glutamyl trans-peptidase (GGT) have shown significant higher values among microalbuminuria subjects and ESRD patients.

In this study, the mean values of total cholesterol and triglycerides were significantly higher among microalbuminuria and macroalbuminuria subjects which was not the case for high-density lipoprotein (HDL) and low-density lipoprotein (LDL), except for those who have ESRD, where they demonstrated significantly lower values.

Glycemic control represented by the values of fasting blood glucose and HbA1c was the worst among subjects with microalbuminuria followed by subjects with microalbuminuria and ESRD. Insulin level was significantly higher among subjects with microalbuminuria, while C-peptide was significantly higher among patients with ESRD. HOMA-IR as indication for insulin resistance was significantly higher in all-stages of diabetic nephropathy (*P*\<.001), while beta cell function expressed by HOMA-B did not show any significant difference.

When looking at the association of different hematological and biochemical parameters with different stages of diabetic nephropathy, the presence of uric acid \>6.8 mg/dL for males and \>6 mg/dL for females was associated with increased risk for microalbuminuria and macroalbuminuria (*P*\<.001). Higher level of LDH was associated with high risk of microalbuminuria (*P*=.009). Insulin resistance presented by HOMA-IR\>4.32 was associated with increased risk of microalbuminuria and ESRD only (*P*=.004). Increased RDW was only associated with ESRD. Increased Hct and WBCs were not associated with any risk for diabetic nephropathy. The low RBCs count and hemoglobin level in both males and females were associated with more than two times increased risk for microalbuminuria (*P*=.013). All the tested parameters were significantly associated with increased risk of ESRD (*P*\<.001), except for higher levels of WBCs count and Hct as seen in [Table 4](#t4-asm-1-46){ref-type="table"}.

DISCUSSION
==========

Since SAUDI-DKD study is aiming to assess clinical and biochemical parameters related to diabetic kidney disease, subjects were recruited using ADA case definition for different stages of diabetic nephropathy namely: microalbuminuria, marcoalbuminuria and ESRD. We started screening of more than 5000 Saudi type 2 diabetic patients to come up with 427 subjects with diabetic kidney disease. The real challenge for the patients' recruitment was to come up with enough number cases with marcoalbuminuria since in this society similar to other societies patients with marcoalbuminuria swiftly go to ESRD.[@b13-asm-1-46]

In consistence with other studies, subjects with diabetic nephropathy were older with longer diabetes duration, and had higher blood pressure which are well-established risk factors for diabetic nephropathy.[@b14-asm-1-46],[@b15-asm-1-46] This observation has been previously reported among a large cohort of Saudi type 2 diabetic patients at a country level.[@b16-asm-1-46] The significantly lower mean BMI among subjects with nephropathy observed in this study could be as a consequence of renal failure.[@b17-asm-1-46] The weight loss observed among patients with diabetic nephropathy, especially among patients with ESRD could result from poor appetite and metabolic acidosis that would reduce both muscle and fat mass.[@b18-asm-1-46]

In consistence with other studies that have shown family history of renal disease as a strong predictor for kidney disease,[@b19-asm-1-46] the current study has shown that the vast majority of patients with positive family history of renal disease were suffering from diabetic nephropathy.

The majority of the studied cohort were married subjects, however with the disease progression and owing to advanced age and longer diabetes duration, the percentage of widows was higher in subjects with ESRD compared with subjects with microalbuminuria and marcoalbuminuria. More than 70% of patients with diabetic nephropathy were in the low and middle social class with monthly income of \<10 000 SR and this observation is even worse among patients with ESRD. This is in consistence with the finding that low socioeconomic status is associated with both the development and progression of chronic kidney disease.[@b20-asm-1-46]

Diabetic retinopathy had the highest frequency among subjects with nephropathy especially in marcoalbuminuria and ESRD which is a well-established association, where microalbumiuria is considered as a state of generalized vascular dysfunction.[@b21-asm-1-46] The presence of vasculopathy was more frequent among patients with diabetic nephropathy, which could be explained on one hand by the fact that both conditions are co-existing traditional risk factors. On the other hand, microvascular diseases promote atherosclerosis through processes such as hypoxia and changes in vasa vasorum. [@b22-asm-1-46] Hypertension affected more than 80% of subjects with nephropathy compared with 50% among patients with normal albumin excretion, which could be due to several mechanisms including the activation of sympathetic nervous system (SNS) and renin-angiotensin-aldosterone system (RAAS), endothelial cell dysfunction (ECD), and excess sodium retention as well as oxidative stress.[@b23-asm-1-46] The hyperlipidemia observed in diabetic patients, which could be secondary to diabetes, may exaggerate the effect of hyperglycemia on the kidney tissue, since the triglyceride-rich lipoprotein may induce glomerular damage through the activation of the transforming growth factor-beta (TGF-β) pathway.[@b24-asm-1-46] It can also activate monocytes and disrupt cellular glycocalyx which exaggerate permeability of the glomerulus.[@b25-asm-1-46] However, the frequency of hyperlipidemia did not show an increasing pattern with the progression of diabetic nephropathy which could reflect using lipid lowering agents among such patients.[@b26-asm-1-46]

Anemia was found to be an independent predictor for progression of diabetic nephropathy in many studies, especially among patients with ESRD.[@b27-asm-1-46] This supports our observation of the significant decrease in the mean concentration of Hb and RBCs count in subjects with microalbuminuria and ESRD which could be due to impaired erythropoietin production and factors that may suppress bone marrow erythropoiesis and shortened red cell survival.[@b28-asm-1-46] This could also explain the significant association that was observed in the current study between the two parameters and different stages of diabetic nephropathy when calculating the OR. Therefore, this hematological changes can be considered an indicative for renal damage in diabetic patients. The picture of anemia observed among the study cohort was more likely to be anemia of chronic diseases for patients with microalbuminuria and marcoalbuminuria, where the mean values of both MCV and MCH were not affected significantly.[@b29-asm-1-46] However, it was more in favor of megaloblastic anemia with high mean values of MCV and MCH among ESRD subjects. Such finding could be due to vitamin B12 deficiency that is associated with poor nutritional intake among dialysis patients, in addition to addition to the fact that patients on dialysis are limited to low B12 foods, since foods rich in B12 are known to contain high concentrations of electrolytes harmful to dialysis patients.[@b30-asm-1-46] Hematocrit, on the other hand decreases with the progression of nephropathy, especially among microalbuminuria and ESRD which could result from fluid retention associated with renal impairment.[@b31-asm-1-46]

Similar to what has been observed among Caucasians, our population also showed a progressive impairment in red blood cell deformability in the current study, especially in microalbuminuria and marcoalbuminuria stages. The impairment of red blood cell deformability could be related to hyperglycemia, accumulation of advanced glycation end products (AGEs), and impaired renal functions.[@b32-asm-1-46] On the other hand, patients with ESRD had shown elevated RDW, which is similar to the finding of Tekce et al, and could be due to adverse effects of inflammation, malnutrition, and excess intradialytic weight gain (IDWG) in the patients being on hemodialysis.[@b33-asm-1-46]

The leukocytosis observed in this study among patients with diabetic nephropathy is similar to what has been reported among Taiwanese type 2 diabetic that could be due to the inflammatory process associated with microangiopathy.[@b34-asm-1-46] The mechanisms for such change could be related to the increased plasma cortisol and insulin levels in renal disease since both are known to increase WBC counts by increasing neutrophil influx from marrow storage and decreasing efflux from the blood stream.[@b35-asm-1-46],[@b36-asm-1-46] Although the literature support the increase in the platelets count with progression of diabetic nephropathy,[@b37-asm-1-46] our study did not demonstrate this finding which could be explained on the basis that impaired erythropoietin secretion decreases the platelet count due to the extensive homology between the erythropoietin and thrombopoietin thus it acts as a humoral regulator of platelet mass.[@b28-asm-1-46] Additionally, the significant drop in platelets counts among patients with ESRD could be a consequence of hemodialysis procedure.[@b38-asm-1-46]

This study did not demonstrate any correlation between DKD and total bilirubin, although direct bilirubin was significantly lower among patients with marcoalbuminuria which is consistent with the observation that hyperbilirubinemia is associated with reduced risk of diabetic nephropathy.[@b39-asm-1-46] Total protein and albumin were significantly higher among patients with microalbuminuria, while they were lower among patients with marcoalbuminuria most likely due to protein loss and may reflect as well nutritional status.

The progression of diabetic kidney disease is associated with increased levels of LDH in this study indicating kidney damage, while increasing GGT reflects endothelial dysfunction that is strongly associated with advanced chronic kidney disease. Therefore, it could be speculated that elevated serum GGT level might be a biomarker rather than a reflection of oxidative stress or inflammatory process.[@b40-asm-1-46],[@b41-asm-1-46]

Insulin resistance has been reported to increase glomerular hydrostatic pressure and renal vascular permeability.[@b42-asm-1-46] This will aggravate glomerular hyper-filtration and enhance renal sodium reabsorption[@b43-asm-1-46] which goes with the current study findings presented by higher insulin and C-peptide level along with high values of HOMA-IR in subjects suffering from marcoalbuminuria and ESRD. In this study the significantly high uric acid level observed among subjects with kidney disease could be secondary to decreased eGFR and increased uric acid reabsorption.[@b44-asm-1-46]

The current study is limited by being cross-sectional study design which only provides the basis for associations rather than causality. Another limitation of this study was excluding patients with some risk factors such as smoking which might affect the generalizability of the study results. On the other hand, this study draws its strength from the large sample size and clearly defined cases. All laboratory assessment were performed in an internationally accredited central laboratory, where all performed test had low intra and inter assay variation coefficient.

In conclusion, the presence of diabetic kidney disease on the top of hyperglycemia would exaggerate its effect on hematological, biochemical and metabolic parameters. This warrants proper monitoring of such patients, especially with their increased risk of anemia with nephropathy progression. Early initiation of lipid lowering agent may be beneficial in preserving renal functions among such patients. Improving insulin sensitivity could be one of the strategies to delay the progression of diabetic nephropathy and it is highly recommended that patients should be advised to take all measures that improve insulin sensitivity. Liver enzymes as well as uric acid level should be monitored frequently among patients with diabetic kidney disease.

Further investigations with longitudinal prospective studies to evaluate the values in these laboratory findings through the course of the disease is recommended.
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###### 

Baseline characteristics of the study subjects according to nephropathy stage.

  Characteristics             Total Sample n=640   Without nephropathy n=213   With nephropathy n=427   *P* value   Microal-buminuria n=184   Macroal-buminuria n=83   ESRD n=160       *P* value
  --------------------------- -------------------- --------------------------- ------------------------ ----------- ------------------------- ------------------------ ---------------- -----------
  Age (years)                 56.64 (6.62)         55.62 (6.00)                57.52 (7.00)             \<.0001     56.46 (6.05)              55.93 (7.77)             59.14 (7.27)     \<.001
  Diabetes duration (years)   18.21 (5.93)         17.25 (5.26)                19.04 (6.33)             \<.0001     18.86 (5.77)              19.52 (6.62)             19.03 (6.77)     .751
  Monthly income (SR)         10097 (7594)         12017 (8171)                8368 (6582)              \<.0001     9877 (6947)               10746 (7067)             5538 (4678)      \<.001
  Height (cm)                 160.50 (9.31)        159.90 (8.80)               161.02 (9.71)            .082        161.73 (9.72)             161.42 (9.55)            160.14 (9.75)    .264
  Weight (kg)                 82.15 (16.48)        83.21(15.34)                81.22 (17.38)            .076        84.91 (16.62)             83.47 (17.55)            76.66 (17.11)    \<.001
  BMI (kg/m^2^)               32.05 (6.20)         32.65 (5.95)                31.52 (6.38)             .008        32.57 (5.88)              31.95 (6.27)             30.27 (6.72)     .002
  Hip (cm)                    109.73 (13.00)       110.06 (12.00)              109.43 (13.84)           .480        110.63 (11.72)            108.36 (14.01)           108.58 (15.71)   .277
  Waist (cm)                  106.37 (12.94)       105.70 (12.05)              106.97 (13.68)           .151        107.95 (11.70)            106.94 (13.10)           105.94 (15.70)   .366
  W/H ratio                   0.97 (0.08)          0.96 (0.08)                 0.98 (0.08)              .002        0.98 (0.07)               0.98 (0.08)              0.98 (0.09)      .941
  SBP (mm Hg)                 137.88 (20.05)       131.56 (17.55)              143.84 (20.46)           \<.001      140.69 (19.35)            147.09 (19.21)           146.26 (21.79)   .014
  DBP (mm Hg)                 72.55 (11.44)        72.29 (9.95)                72.79 (12.68)            .532        74.61 (11.20)             76.03 (13.10)            69.26 (13.37)    \<.001
  eGFR (mL/min/1.73m^2^)      58.13 (41.69)        79.43 (18.44)               47.98 (45.65)            \<.001      79.01 (46.17)             50.14 (21.91)            7.79 (4.32)      \<.001

Data are mean (standard deviation). BMI: body mass index; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; SBP: systolic blood pressure; W/H: waist to hip; SR: Saudi Riyals.

###### 

Clinical and social characteristics by diabetic kidney disease stage.

  Characteristics                        All Subjects n (%)   Without nephropathy n(%)   With nephropathy n(%)   *P* value   Diabetic kidney disease   *P* value                  
  --------------------- ---------------- -------------------- -------------------------- ----------------------- ----------- ------------------------- ------------ ------------- --------
                        Number           640                  213                        427                     184         83                        160                        
  Age                   30-\<45 years    31 (4.84)            9 (4.23)                   22 (5.15)               \<.001      8 (4.35)                  8 (9.64)     6 (3.75)      .001
                        45--60 years     408 (63.75)          164 (77.00)                244 (57.14)                         122 (66.30)               48 (57.83)   74 (46.25)    
                        \> 60 years      201 (31.41)          40 (18.77)                 161 (37.71)                         54 (29.35)                27 (32.53)   80 (50.00)    
  Gender                Male             285 (44.53)          79 (37.09)                 206 (48.24)             .062        84 (45.65)                48 (57.83)   74 (46.25)    .189
                        Female           355 (55.47)          134 (62.91)                221 (51.76)                         100 (54.35)               35 (42.17)   86 (53.75)    
  Diabetes duration     \<15 years       182 (28.44)          73 (34.27)                 109 (25.53)             .017        46 (25.00)                19 (22.89)   44 (27.50)    .411
                        15--30 years     444 (69.38)          138 (64.79)                306 (71.66)                         135 (73.37)               61 (73.49)   110 (68.75)   
                        \>30 years       14 (2.18)            2 (0.94)                   12 (2.81)                           3 (1.63)                  3 (3.62)     6 (3.75)      
  Family history        Diabetes         551 (86.09)          192 (90.14)                359 (84.07)             .036        159 (86.41)               74 (89.16)   126 (83.13)   .793
                        Renal disease    110 (17.19)          39 (18.31)                 71 (16.63)              .052        37 (20.11)                7 (8.43)     27 (16.87)    .005
  Marital status        Single           22 (3.44)            5 (2.35)                   17 (3.98)               \<.001      7 (3.81)                  2 (2.42)     8 (5.00)      .289
                        Married          514 (80.31)          188 (88.26)                326 (76.35)                         141 (76.63)               71 (85.53)   114 (71.25)   
                        Divorced         23 (3.59)            5 (2.35)                   18 (4.22)                           9 (4.89)                  2 (2.42)     7 (4.38)      
                        Widow            81 (12.66)           15 (7.04)                  66 (15.46)                          27 (14.67)                8 (9.63)     31 (19.37)    
  Social class          I                201 (31.41)          43 (20.19)                 158 (37.00)             \<.001      51 (27.72)                21 (25.30)   86 (53.75)    \<.001
                        II               218 (34.06)          73 (34.27)                 145 (33.96)                         64 (34.78)                23 (27.71)   58 (36.25)    
                        III              169 (26.41)          75 (35.21)                 94 (22.01)                          52 (28.26)                28 (33.73)   14 (8.75)     
                        IV               52 (8.12)            22 (10.33)                 30 (7.03)                           17 (9.24)                 11 (13.26)   2 (1.25)      
  DM complications      Neuropathy       323 (50.47)          106 (49.77)                217 (50.82)             .38         96 (52.17)                42 (50.60)   79 (49.38)    .863
                        Retinopathy      341 (53.28)          63 (29.58)                 278 (65.11)             \<.001      97 (52.27)                59 (71.08)   122 (76.25)   \<.001
                        Vasculopathy     138 (21.56)          15 (7.04)                  123 (28.81)             \<.001      40 (21.74)                25 (30.12)   58 (36.25)    \<.001
  Associated diseases   Hypertension     477 (74.53)          119 (55.87)                358 (83.84)             \<.001      144 (78.26)               69 (83.13)   145 (90.63)   .003
                        Hyperlipidemia   32 (5.00)            9 (4.23)                   23 (5.39)               \<.001      9 (4.89)                  8 (9.64)     6 (3.75)      .062

Data are mean (standard deviation) or number (percentage). ESRD: end-stage renal disease.

###### 

Hematology, biochemistry and lipid parameters by diabetic kidney disease group.

  Parameters (measurement, unit)   No kidney disease      Diabetic kidney disease   Total            Micro-albuminuria   *P* value        Macro-albuminuria   *P* value         ESRD     *P* value         
  -------------------------------- ---------------------- ------------------------- ---------------- ------------------- ---------------- ------------------- ----------------- -------- ----------------- --------
  Complete blood count             WBC (10^9^/L)          6.81 (2.47)               6.43 (2.37)      6.99 (2.50)         6.92 (2.74)      .048                7.30 (2.79)       .015     6.92 (2.39)       .057
                                   RBC (10^12^/L)         4.63 (0.95)               4.89 (0.68)      4.51 (1.03)         4.85 (0.87)      .647                4.65 (0.97)       .053     4.04 (1.06)       \<.001
                                   Hb (%)                 12.79 (2.63)              13.41 (2.49)     12.50 (2.66)        13.36 (2.18)     .809                12.59 (2.38)      .013     11.47 (2.93)      \<.001
                                   Platelets (10^9^/L)    268.26 (79.71)            272.42 (76.88)   266.16 (81.20)      275.96 (75.15)   .650                276.32 (88.94)    .717     249.71 (81.82)    .008
                                   Hct (%)                39.47 (8.61)              41.74 (7.37)     38.41 (8.96)        41.08 (8.29)     .410                38.13 (7.17)      \<.001   35.40 (9.60)      \<.001
                                   MCV (fL)               85.61(8.18)               85.61 (9.94)     85.62 (7.20)        84.83 (7.58)     .386                83.38 (7.07)      .036     87.71 (6.24)      .015
                                   MCH (pg/cell)          28.04 (2.85)              27.58 (3.35)     28.27 (2.56)        28.22 (2.64)     .035                27.43 (2.41)      .674     28.75 (2.43)      \<.001
                                   MCHC (g/dL)            32.71 (2.27)              32.37 (2.74)     32.86 (1.99)        32.78 (2.28)     .110                33.02 (2.12)      .037     32.86 (1.50)      .032
                                   RDW-SD (fL)            44.67 (5.09)              44.22 (5.23)     44.87 (5.04)        43.58 (4.78)     .241                42.40 (4.61)      .011     47.35 (4.41)      \<.001
                                   RDW-CV (%)             14.35 (1.19)              14.33 (1.27)     14.36 (1.15)        14.11 (1.05)     .089                13.91 (0.93)      .004     14.83 (1.18)      \<.001
                                   MPV (fL)               11.78 (1.49)              11.85 (1.58)     11.75 (1.45)        11.81 (1.59)     .800                11.64 (1.53)      .297     11.75 (1.23)      .468
                                   PCT (%)                0.33 (0.10)               0.33 (0.10)      0.32 (0.10)         0.34 (0.10)      .652                0.33 (0.10)       .879     0.30 (0.09)       \<.001
  Renal function                   Na (mmol/L)            146.41 (12.62)            144.59 (7.73)    147.199 (14.18)     148.50 (7.73)    \<.001              144.057 (8.99)    .660     147.03 (18.69)    .125
                                   K (mmol/L)             4.98 (0.82)               4.54 (0.48)      5.18 (0.86)         4.74 (0.43)      \<.001              4.95 (0.57)       \<.001   5.81 (0.96)       \<.001
                                   Ca (mg/dL)             10.63 (2.15)              10.27 (1.83)     10.80 (2.27)        11.37 (1.35)     \<.001              10.70 (2.65)      .201     10.25 (2.68)      .944
                                   Urea (mg/dL)           61.54 (50.85)             29.49 (15.13)    76.53 (54.72)       38.49 (17.51)    \<.001              57.95 (35.19)     \<.001   133.50 (45.02)    \<.001
                                   Creatinine (mg/dL)     2.63 (2.87)               0.96 (0.28)      3.42 (3.19)         1.15 (0.85)      .004                1.71 (1.00)       \<.001   7.02 (2.36)       \<.001
                                   Uric acid (mg/dL)      5.69 (1.70)               4.79 (1.33)      6.11 (1.69)         5.62 (1.63)      \<.001              6.42 (1.84)       \<.001   6.55 (1.53)       \<.001
                                   ACR (mg/g)             98.00 (123.18)            10.67 (10.18)    165.45 (128.16)     111.31 (73.43)   \<.001              357.89 (95.47)    \<.001   188.13 (112.28)   .012
  Liver function tests             D bilirubin (mg/dL)    0.07 (0.09)               0.07 (0.09)      0.07 (0.09)         0.07 (0.11)      .811                0.04 (0.06)       .001     0.08 (0.07)       .270
                                   T bilirubin (mg/dL)    0.47 (0.21)               0.45 (0.24)      0.47 (0.20)         0.48 (0.23)      .213                0.43 (0.21)       .398     0.48 (0.16)       .140
                                   T protein (g/L)        71.87 (9.88)              71.19 (10.33)    72.25 (9.67)        73.95 (10.42)    .009                72.03 (8.22)      .518     70.29 (9.07)      .384
                                   Albumin (g/L)          43.33 (6.39)              43.78 (4.28)     43.15 (7.17)        45.37 (7.12)     .008                43.50 (6.21)      .703     40.24 (6.70)      \<.001
                                   ALT (U/L)              12.65 (7.94)              13.91 (7.79)     12.09 (7.97)        13.12 (8.27)     .328                12.96 (6.32)      .290     10.39 (8.10)      \<.001
                                   AST (U/L)              22.73 (9.52)              22.48 (8.69)     22.87 (9.92)        23.69 (9.73)     .194                23.06 (6.93)      .593     21.74 (11.31)     .500
                                   LDH (U/L)              163.57 (60.03)            140.40 (51.16)   174.70 (60.78)      153.49 (56.34)   .016                174.40 (48.70)    \<.001   201.33 (61.72)    \<.001
                                   GGT (U/L)              42.28 (30.23)             36.45 (25.61)    45.02 (31.88)       36.87 (22.83)    .864                47.35 (29.08)     .002     53.52 (39.37)     \<.001
  Lipid profile                    Cholesterol (mg/dL)    181.25 (45.94)            174.34 (36.51)   184.77 (49.43)      190.10 (52.47)   .001                195.11 (46.34)    .001     173.12 (44.91)    .776
                                   HdL (mg/dL)            45.27 (13.03)             45.89 (11.67)    45.06 (13.64)       47.45 (13.93)    .228                44.95 (11.93)     .546     42.12 (13.61)     .006
                                   LdL (mg/dL)            124.78 (41.88)            131.79 (41.20)   121.65 (41.92)      130.44 (42.58)   .751                130.46 (38.92)    .806     106.97 (38.54)    \<.001
                                   Triglyceride (mg/dL)   183.13 (89.43)            155.91 (62.29)   195.93 (97.16)      188.00 (90.83)   \<.001              218.40 (100.83)   \<.001   194.32 (101.60)   \<.001
  Metabolic markers                FBS (mg/dL)            216.32 (93.53)            188.63 (74.85)   230.07 (98.44)      230.64 (92.58)   \<.001              243.96 (103.63)   \<.001   222.35 (102.36)   .001
                                   HbA1c (%)              10.40 (2.06)              10.13 (1.51)     10.52 (2.27)        10.86 (1.95)     \<.001              11.44 (2.45)      \<.001   9.65 (2.26)       .023
                                   Insulin (uIU/mL)       35.07 (32.72)             33.50 (32.66)    35.70 (32.53)       29.53 (28.36)    .195                46.82 (4.023)     .010     37.22 (30.72)     .313
                                   C-peptide (ng/mL)      1.68 (2.55)               0.63 (0.68)      2.16 (2.92)         0.68 (0.98)      .622                0.69 (0.67)       .509     4.64 (3.44)       \<.001
                                   HOMA-IR                4.40 (10.20)              2.95 (2.20)      5.23 (12.65)        4.16 (3.50)      \<.001              8.03 (24.87)      \<.001   5.35 (11.76)      .057
                                   HOMA-B                 63.88 (63.42)             65.85 (53.35)    62.79 (68.44)       59.69 (72.33)    .408                51.49 (53.22)     .111     73.67 (68.11)     .307

Mean (standard deviation). ACR: albumin creatinine ratio; ALT: alanine aminotransferase; AST: aspartate aminotransferase; D bilirubin: direct bilirubin; FBS: fasting blood glucose; GGT: gamma-glutamyl transpeptidase; Hb: hemoglobin; HbA1c: hemoglobin A1c; Hct: hematocrit; HdL high-density lipoprotein; HOMA B: homeostatic model assessment β-cell function (B); HOMA IR: homeostatic model assessment insulin resistance; LDH: lactate dehydrogenase; LdL: low-density lipoprotein; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; MCV: mean corpuscular volume; MPV: mean platelet volume; PCT: plateletcrit; RBC: red blood cells; RDW: RDW-CV: Red blood cell distribution width coefficient of variation; RDW-SD: Red blood cell distribution width standard discrepancy; SD: standard deviation; T bilirubin: total bilirubin; T protein: white blood cells. *P* value was calculated between patients with and without diabetic kidney disease.

###### 

Multinomial logistic regression analysis of factors associated with different types of nephropathy.

  Risk factors                         Microalbuminuria     Macroalbuminuria   ESRD                                               
  ------------------------------------ -------------------- ------------------ ------------------- -------- --------------------- --------
  Uric acid for males \>6.8 mg/dL      6.30 (2.25--17.54)   \<.001             3.97 (1.58--9.99)   \<.001   13.42 (5.04--35.70)   \<.001
  Uric acid for females \>6.0 mg/ dL   4.70 (2.04--10.83)   \<.001             1.67 (0.82--3.41)   .161     11.30 (4.90--26.09)   \<.001
  LDH \>190 U/L                        2.33 (1.23--4.39)    .009               1.37 (0.81--2.32)   .246     7.34 (4.19--12.85)    \<.001
  HOMA-IR ≥4.32                        1.85 (0.86--3.96)    .116               2.11 (1.23--3.62)   .007     2.57 (1.34--4.90)     .004
  WBCs count \>11 10^9^/L              1.82 (0.57--5.86)    .313               1.41 (0.52--3.78)   .499     1.10 (0.32--3.75)     .877
  RBCs count \<4.7 10^12^/L            1.190 (0.72--1.99)   .496               2.40 (1.20--4.78)   .013     13.26 (5.83--30.15)   \<.001
  Hemoglobin for females \<12%         1.14 (0.56--2.32)    .718               2.82 (1.07--7.38)   .035     7.77 (3.33--18.12)    \<.001
  RDW ≥14.5%                           0.72 (0.38--1.38)    .329               0.87 (0.54--1.39)   .562     2.84 (1.70--4.74)     \<.001
  Hemoglobin for males \<13%           0.71 (0.26--1.96)    .508               3.62 (1.20--4.78)   .019     19.66 (5.89--65.60)   \<.001
  Hct ≥52%                             0.57 (0.11--2.87)    .497               1.45 (0.57--3.69)   .437     1.01 (0.33--3.15)     .981

Hb: hemoglobin; Hct: hematocrit; HOMA B: homeostatic model assessment b-cell function (B); HOMA IR: homeostatic model assessment insulin resistance LDH: lactate dehydrogenase; RBC: red blood cells; RDW: Red blood cell distribution width; WBC: white blood cells.

Adjust for age, diabetes duration, BMI, SBP and DBP.

Model-fitting information: −2 Log Likelihood:Uric Acid for males \>6.8 μmol/L: 772.2; Uric Acid for females ≥6.8 μmol/L: 772.2; 1670.0; LDH \>190 U/L: 1670.0; HOMA-IR ≥4.32: 1057.5; WBCs count \>11×10^9^/L:1635.8; RBCs\<4.7 1012 /L: 1622.6; Hemoglobin for females \<12%: 857.8; RDW ≥14.5%: 1498.6; Hemoglobin for Male \<13%: 758.0; HCT ≥ 53%: 622.2
